2022 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2022-09-24±³À°ÀÏÀÚ : 2022-09-24
±³À°Àå¼Ò : ÇѾç´ëÇб³ HIT ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2022 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸¸¼º°ñ¼ö¼º¹éÇ÷º´¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 09:10~09:50 TKI(tyrosine kinase inhibitor) resistance after multi-TKI failure vs. the strategy to improve TFR(total fertility rate) ±è°æÇÏ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 09:50~10:05 Korean BCR/ABL1 RQ-PCR(real-time quantitative polymerase chain reaction) harmonization ±èÇö¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 10:05~10:20 ASTER-P ¹Ú¼º¿ì(°æ»óÀÇ´ë)
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 10:20~10:35 ASTER-A ¾öÁöÀº(ÇѾçÀÇ´ë)
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 10:35~10:50 Ponatinib as 2nd or beyond lines-retrospective ÀÌÁ¤¿Á(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 11:05~11:25 Ponatinib after 2G TKI failure-prosepective (K-POP) ÀÌÁ¤¿Á(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 11:25~11:45 HBV(hepatitis B virus) prophylaxis ±èÇõ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 11:45~12:05 Dasatinib dose optimization ±è»ó¾Æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 12:05~12:25 NGS(next generation sequencing) for ABL1 mutation ½Å»õ¾Ï(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-24 ´ëȸÀÇ½Ç 12:25~12:45 Imatinib as 1st line therapy in very elderly CML(chronic myeloid leukemia) Á¶ÁøÇö(ÀÎÇÏÀÇ´ë)